311 related articles for article (PubMed ID: 26491255)
1. The clinicopathological significance and drug target potential of FHIT in breast cancer, a meta-analysis and literature review.
Su Y; Wang X; Li J; Xu J; Xu L
Drug Des Devel Ther; 2015; 9():5439-45. PubMed ID: 26491255
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological significance and potential drug target of CDH1 in breast cancer: a meta-analysis and literature review.
Huang R; Ding P; Yang F
Drug Des Devel Ther; 2015; 9():5277-85. PubMed ID: 26425077
[TBL] [Abstract][Full Text] [Related]
3. Analysis of FHIT gene methylation in egyptian breast cancer women: association with clinicopathological features.
Zaki SM; Abdel-Azeez HA; El Nagar MR; Metwally KA; S Ahmed MM
Asian Pac J Cancer Prev; 2015; 16(3):1235-9. PubMed ID: 25735361
[TBL] [Abstract][Full Text] [Related]
4. The clinicopathological significance and ethnic difference of FHIT hypermethylation in non-small-cell lung carcinoma: a meta-analysis and literature review.
Wu X; Wu G; Yao X; Hou G; Jiang F
Drug Des Devel Ther; 2016; 10():699-709. PubMed ID: 26929601
[TBL] [Abstract][Full Text] [Related]
5. An early biomarker and potential therapeutic target of RUNX 3 hypermethylation in breast cancer, a system review and meta-analysis.
Lu DG; Ma YM; Zhu AJ; Han YW
Oncotarget; 2017 Mar; 8(13):22166-22174. PubMed ID: 27825140
[TBL] [Abstract][Full Text] [Related]
6. The clinicopathological significance of FHIT hypermethylation in non-small cell lung cancer, a meta-analysis and literature review.
Yan W; Xu N; Han X; Zhou XM; He B
Sci Rep; 2016 Jan; 6():19303. PubMed ID: 26796853
[TBL] [Abstract][Full Text] [Related]
7. Promoter methylation status of the FHIT gene and Fhit expression: association with HER2/neu status in breast cancer patients.
Jeong YJ; Jeong HY; Lee SM; Bong JG; Park SH; Oh HK
Oncol Rep; 2013 Nov; 30(5):2270-8. PubMed ID: 23969757
[TBL] [Abstract][Full Text] [Related]
8. The expression of Fhit protein is related inversely to disease progression in patients with breast carcinoma.
Gatalica Z; Lele SM; Rampy BA; Norris BA
Cancer; 2000 Mar; 88(6):1378-83. PubMed ID: 10717620
[TBL] [Abstract][Full Text] [Related]
9. Quantitative detection of methylation of FHIT and BRCA1 promoters in the serum of ductal breast cancer patients.
Liu L; Sun L; Li C; Li X; Zhang Y; Yu Y; Xia W
Biomed Mater Eng; 2015; 26 Suppl 1():S2217-22. PubMed ID: 26406001
[TBL] [Abstract][Full Text] [Related]
10. FHIT promoter methylation status, low protein and high mRNA levels in patients with non-small cell lung cancer.
Czarnecka KH; Migdalska-Sęk M; Domańska D; Pastuszak-Lewandoska D; Dutkowska A; Kordiak J; Nawrot E; Kiszałkiewicz J; Antczak A; Brzeziańska-Lasota E
Int J Oncol; 2016 Sep; 49(3):1175-84. PubMed ID: 27572663
[TBL] [Abstract][Full Text] [Related]
11. Two-hit inactivation of FHIT by loss of heterozygosity and hypermethylation in breast cancer.
Yang Q; Nakamura M; Nakamura Y; Yoshimura G; Suzuma T; Umemura T; Shimizu Y; Mori I; Sakurai T; Kakudo K
Clin Cancer Res; 2002 Sep; 8(9):2890-3. PubMed ID: 12231533
[TBL] [Abstract][Full Text] [Related]
12. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung.
Kim JS; Kim H; Shim YM; Han J; Park J; Kim DH
Carcinogenesis; 2004 Nov; 25(11):2165-71. PubMed ID: 15231689
[TBL] [Abstract][Full Text] [Related]
13. Fragile genes as biomarkers: epigenetic control of WWOX and FHIT in lung, breast and bladder cancer.
Iliopoulos D; Guler G; Han SY; Johnston D; Druck T; McCorkell KA; Palazzo J; McCue PA; Baffa R; Huebner K
Oncogene; 2005 Feb; 24(9):1625-33. PubMed ID: 15674328
[TBL] [Abstract][Full Text] [Related]
14. DNA methylation and breast tumor clinicopathological features: The Western New York Exposures and Breast Cancer (WEB) study.
Callahan CL; Wang Y; Marian C; Weng DY; Eng KH; Tao MH; Ambrosone CB; Nie J; Trevisan M; Smiraglia D; Edge SB; Shields PG; Freudenheim JL
Epigenetics; 2016 Sep; 11(9):643-652. PubMed ID: 27245195
[TBL] [Abstract][Full Text] [Related]
15. FHIT gene and flanking region on chromosome 3p are subjected to extensive allelic loss in Egyptian breast cancer patients.
Ismail HM; Medhat AM; Karim AM; Zakhary NI
Mol Carcinog; 2011 Aug; 50(8):625-34. PubMed ID: 21557333
[TBL] [Abstract][Full Text] [Related]
16. Mutational and promoter hypermethylation status of FHIT gene in breast cancer patients of Kashmir.
Syeed N; Husain SA; Sameer AS; Chowdhri NA; Siddiqi MA
Mutat Res; 2011 Feb; 707(1-2):1-8. PubMed ID: 21095196
[TBL] [Abstract][Full Text] [Related]
17. The Clinical Relevance of Fragile Histidine Triad Protein (FHIT) in Patients with Bladder Cancer.
Liu XP; Yin XH; Yan XH; Zeng XT; Wang XH
Med Sci Monit; 2018 May; 24():3113-3118. PubMed ID: 29752880
[TBL] [Abstract][Full Text] [Related]
18. Expression and clinical significance of miRNAs that may be associated with the FHIT gene in breast cancer.
Sevinc ED; Cecener G; Ak S; Tunca B; Egeli U; Gokgoz S; Tolunay S; Tasdelen I
Gene; 2016 Sep; 590(2):278-84. PubMed ID: 27236032
[TBL] [Abstract][Full Text] [Related]
19. Clinicopathological significance and potential drug target of RUNX3 in breast cancer.
Yu YY; Chen C; Kong FF; Zhang W
Drug Des Devel Ther; 2014; 8():2423-30. PubMed ID: 25525332
[TBL] [Abstract][Full Text] [Related]
20. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
